LLY Dec 2026 500.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:11AM EDT. Market open.
Loading interactive chart…
- PR Newswire
Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease
Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's disease treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab, regardless of prior biologic experience. VIVID-1 is the first Phase 3 study for any approved or investigational treatment in Crohn's disease to report histologic and combined histologic-endoscopic outcomes that were evaluated using a systematic assessment of five bowel segments (fo
- Yahoo Finance UK
Starmer vows to slash red tape as UK investment summit begins
Companies such as Google parent Alphabet, BlackRock and Brookfield Asset Management are set to be in attendance.
- Simply Wall St.
Boasting A 54% Return On Equity, Is Eli Lilly and Company (NYSE:LLY) A Top Quality Stock?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
© 2024 Yahoo. All rights reserved.